These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31243520)

  • 1. Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study.
    Sehr T; Akgün K; Proschmann U; Bucki R; Zendzian-Piotrowska M; Ziemssen T
    J Mol Med (Berl); 2019 Sep; 97(9):1263-1271. PubMed ID: 31243520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
    Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
    Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
    Matko S; Akgün K; Tonn T; Ziemssen T; Odendahl M
    Mult Scler Relat Disord; 2020 Feb; 38():101859. PubMed ID: 31855843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
    Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L
    Neurology; 2015 Apr; 84(16):1639-43. PubMed ID: 25809304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod induces neuroprotective factors in human astrocytes.
    Hoffmann FS; Hofereiter J; Rübsamen H; Melms J; Schwarz S; Faber H; Weber P; Pütz B; Loleit V; Weber F; Hohlfeld R; Meinl E; Krumbholz M
    J Neuroinflammation; 2015 Sep; 12():184. PubMed ID: 26419927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.
    Chun J; Kihara Y; Jonnalagadda D; Blaho VA
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():149-170. PubMed ID: 30625282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis.
    Ghadiri M; Rezk A; Li R; Evans A; Giacomini PS; Barnett MH; Antel J; Bar-Or A
    Sci Rep; 2020 Jan; 10(1):356. PubMed ID: 31941953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment.
    Leo A; Citraro R; Marra R; Palma E; Paola EDD; Constanti A; De Sarro G; Russo E
    CNS Neurol Disord Drug Targets; 2017; 16(3):311-325. PubMed ID: 27823573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
    Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
    PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.
    Bordet R; Camu W; De Seze J; Laplaud DA; Ouallet JC; Thouvenot E
    Rev Neurol (Paris); 2020; 176(1-2):100-112. PubMed ID: 31757428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from S1P receptor targeting in multiple sclerosis.
    Colombo E; Farina C
    Pharmacol Ther; 2022 Feb; 230():107971. PubMed ID: 34450231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
    Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
    Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
    Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
    Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and Optimization of
    Gusman DH; Shoemake C
    Yale J Biol Med; 2017 Mar; 90(1):15-23. PubMed ID: 28356890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
    Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
    CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.